We report here the cloning and characterization of human and mouse cyclin E2, which de®ne a new subfamily within the vertebrate E-type cyclins, while all previously identi®ed family-members belong to the cyclin E1 subfamily. Cyclin E2/CKD2 and cyclin E/CDK2 complexes phosphorylate histone H1 in vitro with similar speci®c activities and both are inhibited by p27 Kip1 . Cyclin E2 mRNA levels in human cells oscillate throughout the cell cycle and peak at the G1/S boundary, in parallel with the cyclin E mRNA. In cells, cyclin E2 is complexed with CDK2, p27 and p21. Like cyclin E, cyclin E2 is an unstable protein in vivo and is stabilized by proteasome inhibitors. Cyclin E2-associated kinase activity rises in late G1 and peaks very close to cyclin E activity. In two malignantly transformed cell lines, cyclin E2 activity is sustained throughout S phase, while cyclin E activity has already declined and cyclin A activity is only beginning to rise. We speculate that cyclin E2 is not simply redundant with cyclin E, but may regulate distinct rate-limiting pathway(s) in G1-S control.
Introduction
Passage through the G1 and S phases of the mammalian cell cycle depends upon the activities of the cyclin-dependent kinases CDK4 and CDK6, associated with D-type cyclins (D1 ± D3), and CDK2, associated with cyclins E and A (Pagano et al., 1992; Baldin et al., 1993; van den Heuvel and Harlow, 1993; Lukas et al., 1994; Ohtsubo et al., 1995;  for reviews see Sherr, 1994; . CDK3, most closely related in sequence to CDK2 (Meyerson et al., 1992) , is also required for G1-S progression (van den Heuvel and Harlow, 1993; Hofmann and Livingston, 1996) and is activated in G1 (Braun et al., 1998) . However, the identity of the cyclin-partner(s) of CDK3 in vivo remains unknown, although cyclin E can activate CDK3 in vitro (Harper et al., 1995) . Activation of CDKs requires not only cyclin binding, but also dephosphorylation of two conserved residues (Thr 14 and Tyr 15 in CDK2) by cdc25-family phosphatases and phosphorylation of another conserved residue (Thr 160 in CDK2) by CDK-activating kinase (CAK) (e.g. Gu et al., 1992; reviewed in Morgan, 1995; Solomon and Kaldis, 1998) . Cyclin/CDK complexes are also regulated by two families of inhibitory proteins (CKIs) (Morgan, 1995; Sherr and Roberts, 1995) . The Cip/Kip family includes p21 Cip1 , p27 Kip1 and p57 Kip2 , which associate with all G1-cyclin/CDK complexes. The INK4 family includes p16 INK4a , p15 INK4b , p18
INK4c and p19 INK4d , which bind to CDK4 and CDK6. The ability of p21 Cip1 and p27 Kip1 to inhibit CDK2 is regulated at various levels in cells. Biosynthesis of p21 Cip1 appears to be regulated mostly at the transcriptional level (Sherr and Roberts, 1995) , while p27
Kip1 is subject to translational control (Agrawal et al., 1996; Hengst and Reed, 1996; Millard et al., 1997) . Both CKIs may also be degraded via the ubiquitin/ proteasome pathway Maki and Howley, 1997) . Phosphorylation of p27 Kip1 by Cyclin E/ CDK2 can trigger its degradation in vivo (Shea et al., 1997; Vlach et al., 1997) , as also demonstrated for cyclin E degradation (Clurman et al., 1996; Won and Reed, 1996) . Furthermore, the inhibitory function of p21 and p27 can be modulated by proteins which sequester these CKIs and prevent their association with cyclin E/CDK2. This eect can be mediated either by D-type cyclins (Polyak et al., 1994a; Reynisdottir et al., 1995; Blain et al., 1997; Reynisdottir and MassagueÂ , 1997) or, in response to ectopic expression of the cMyc oncoprotein, by yet unknown cellular proteins (Vlach et al., 1996; PeÂ rez-Roger et al., 1997; Gaillard, Vlach and Amati, unpublished data) . In an attempt to identify new p27-interacting proteins, we performed a two-hybrid screen in yeast. We report the identi®cation of a new mammalian cyclin, cyclin E2, and its characterization as a functional partner of CDK2 in human cells.
Results and Discussion
The human p27
Kip1 protein was used as bait in a yeast two-hybrid screen using a human B-cell lymphoma cDNA library (data not shown; see Materials and methods). We isolated a cDNA fragment encoding a polypeptide with high homology to the cyclin-box domain of cyclin E (dashed line, Figure 1a ). Longer cDNAs were obtained by hybridization of the same library and by computer screens for expressed sequence tags. Overlapping cDNAs were sequenced. The fulllength cDNA (accession no. AF091433) encoded a protein of 404 amino acids which we termed cyclin E2.
The start-codon was preceded by an in-frame stopcodon, indicating that the entire reading frame had been isolated. This feature was conserved in the mouse cDNA (accession no. AF091432), isolated by PCR from a mouse brain cDNA library, based on the sequence of mouse genomic clones (A Beck and B Amati, unpublished). Mouse and human cyclin E2 are highly conserved (92% identity; Figure 1a ). Among the cyclin family, cyclin E2 is most closely related to cyclin E (Figure 1a and b) . The highest similarity resides in the cyclin box (residues 137 ± 238 of cyclin E2, 75% identity with E), followed by the second cyclin-fold (Jerey et al., 1995) (res. 239 ± 358, 56% identity) and the amino and carboxy-termini (26% in either case; Figure 1a ). In evolutionary terms, mammalian cyclins E and E2 diverged from each-other prior to the radiation of vertebrates ( Figure 1b) ; cyclin E2 genes are thus likely to exist in other vertebrate species. (Saitou and Nei, 1987) derived from the cyclin-box and second cyclin-fold sequences (residues 137 ± 358 in cyclin E2) of representative E-type cyclins. Note that all previously known vertebrate members, including Xenopus E1 and E3, belong to the E1 subfamily. Human cyclin A, as a representative of A-type cyclins, was used as an outgroup. Other cyclin families (e.g. B, D) are more distantly related to E-type cyclins. Gap regions and poorly conserved parts of the cyclin box alignment were excised prior to dendrogram construction. EMBL/Genbank accession numbers for the cyclins shown are: human E: M73812; mouse E: X75888; frog E1: L43512 (also in Z13966, L23857); frog E3: L43513; chicken E: U28981; zebra®sh E: X83594; Drosophila E: X75026; human A: X51688; human E2: AF091433 and mouse E2: AF091432 However, cyclins E and E2 are each equally distant from Drosophila cyclin E, suggesting that the E1 and E2 subfamilies arose by gene duplication after the separation from Drosophila (Figure 1a and b).
Antisera were raised against three distinct peptides derived from the human cyclin E2 sequence and characterized using baculovirus-expressed human cyclins E2, E, A and CDK2. Anti-cyclin E2 sera (numbered 2b, 3b, 4b and 6) speci®cally recognized cyclin E2 on immunoblots (Figure 2a , see legend) and immunoprecipitated histone H1-kinase activity only in the presence of cyclin E2 and CDK2 (Figure 2b ). Immunoprecipitates of either cyclin E or E2 contained CDK2 protein, and both complexes showed similar histone H1-kinase activities when normalized to the amount of associated CDK2 (Figure 2c ). Similar activities were also obtained by performing kinase assays directly in lysates of Sf9 cells expressing cyclin E or E2 along with CDK2, and by using as substrate a recombinant Retinoblastoma protein (GST-Rb; Figure  2d ). In Sf9 lysates, cyclin E2 also activated CDK1 (CDC2) and CDK3 (data not shown). However, unlike with CDK2, we were unable to demonstrate speci®c complexes between cyclin E2 and either CDK1 or CDK3 in human cells. Thus, the physiological relevance of these in vitro activities remains uncertain. Finally, when added to insect cell lysates, recombinant p27 inhibited cyclin E2/CDK2 and cyclin E/CDK2 with the same dose-dependencies ( Figure 2e ). p27 ck-, a mutant defective in cyclin-and CDK-interactions (Vlach et al., 1997) , was unable to inhibit either complex. Titration experiments showed that cyclin E/ CDK2 and cyclin E2/CDK2 complexes reciprocally competed with each-other for p27 binding (N Lauper, J Vlach and B Amati, unpublished data). In conclusion, cyclin E2 is undistinguishable from cyclin E in its ability to activate CDK2 and its susceptibility to inhibition by p27 in vitro.
Analysis of various cell lines by immunoblotting with the available anti-E2 sera (with or without prior immunoprecipitation) did not allow direct visualization of the endogenous cyclin E2 protein ( Figure 3a , lane 1; data not shown). Transfection of 293T cells with a cyclin E2-expressing plasmid barely allowed detection of the protein ( Figure 3a , lane 2), but treatment of the transfected cells with the proteasome inhibitor LLnL induced a strong accumulation of exogenous cyclin E2 ( Figure 3a , lane 4). Thus, cyclin E2 is an unstable protein in vivo and is probably degraded via the ubiquitin/proteasome pathway. Phosphorylation of cyclin E by CDK2 on Threonine 395 triggers its release from CDK2 and degradation via the ubiquitin/ proteasome pathway (Clurman et al., 1996; Won and Reed, 1996) . Notably, this CDK2 target site (TPPQ) is conserved in cyclin E2 as TPPK (Thr 392; Figure 1a) . Mutation of Threonine 392 to Valine led to a slight increase in cyclin E2 protein levels following transfection of the mutant allele into 293T cells (data not shown). Co-expression of exogenous p27 led to a similar increase in cyclin E2 levels (Figure 3a , compare lanes 2 and 8). Thus, similar mechanisms may operate for degradation of cyclins E and E2. Finally, and most importantly, treatment with LLnL allowed detection of cellular cyclin E2, albeit at very low levels ( Figure 3a , lane 3). Endogenous and exogenous cyclin E2 were recognized by other anti-E2 sera and co-migrated in SDS ± PAGE with an apparent molecular weight of 47 ± 48 kd (predicted: 46.7 kd), similar to that of the baculovirus-expressed protein (data not shown). We conclude that cyclin E2 is expressed in human cells. Figure 2 Characterization of anti-cyclin E2 antibodies and biochemical characterization of cyclin E2. (a) Human cyclins E2, E or A were expressed in insect cells (Sf9) with recombinant baculoviruses, as indicated (bac). Equal amounts of Sf9 lysates were used for immunoblotting with antibodies against the various cyclins, as indicated (blot) with sera 2b, 3b, 4b and 6, raised against dierent cyclin E2 peptides (see Materials and methods). Note that these antisera did not cross-react with recombinant cyclins E or A, except for a faint cross-reactivity of 2b with cyclin E. However, 2b did not detect cyclin E on immunoblots following its immunoprecipitation from human cells (data not shown) and did not immunoprecipitate cyclin E/CDK2 complexes. (b) Cyclins were expressed together with CDK2 (K2) as indicated (bac) and immunoprecipitated from Sf9 lysates with the indicated antibodies (IP), followed by histone H1-kinase assays. Phosphorylated histone H1 is shown (H1). As control, each anti-cyclin E2 antibody was pre-blocked with its cognate immunogenic peptide (lane 2, asterisk). (c) Cyclins E or E2 (antiserum 6) were immunoprecipitated from the indicated Sf9 lysates (bac) and used for immunoblotting with anti-CDK2 antibodies (upper panels) or assaying histone H1 phosphorylation (H1). Ig: immunoglobulin heavy chains. (d) Phosphorylation of histone H1 or GST-Rb was assayed directly Sf9 lysates (bac) expressing the indicated proteins. (e) The indicated amounts (ng) of wild type p27
Kip1 or the mutant p27 ck- (Vlach et al., 1997) were added directly to Sf9 lysates containing cyclins E2 or E together with CDK2, followed by a pre-incubation (15 min, 308C) and H1-kinase assays Immunoprecipitation of cyclin E2 from 293T cells with either of the anti-E2 sera allowed detection of cyclin E2-associated H1-kinase activity and CDK2 protein (Figure 3b ). Both associations were speci®c, since they were eliminated by pre-blocking each antibody with its cognate peptide. p27
Kip1 and p21
Cip1 also speci®cally co-precipitated with cyclin E2 (data not shown; Figure 4c and d). Cyclin E2-associated kinase activity was detectable in various proliferating cell lines, and no obvious correlation (direct or inverse) was seen between cyclin E and E2 activities (Figure 3c ). Strikingly, although cyclin E2 was detected at very low total levels in 293T cells, the amounts of cyclin E2-and E-associated CDK2, as well as their kinase activities, were comparable (Figure 3b ). (Figure 3d, upper panel) . However, similar amounts of E HA and E2
HA -associated kinase activities were recovered by anti-HA immunoprecipitation (Figure 3d, lower panel) . Consistent with this result, similar amounts of CAK-phosphorylated (active) endogenous CDK2 were associated with E HA and E2
HA (Figure 3d , lower CDK2 band; Gu et al., 1992) , although more non-phosphorylated inactive CDK2 was bound to overexpressed E HA (Figure 3d , upper CDK2 band). Thus, both endogenous and exogenous cyclin E2 eectively associate with, and activate CDK2 in cells. The fact that cyclin E2 accumulates at much lower levels than cyclin E suggests that, when uncomplexed, cyclin E2 may be more rapidly degraded. We have been unable so far to detect association of either endogenous cyclin E2 or exogenous E2
HA with CDK1, CDK3 or CDK4 in cells (except for a faint interaction of E2
HA with overexpressed CDK3; data not shown). Thus, whether either cyclins E2 or E are physiological CDK3 partners remains uncertain. Altogether, our data demonstrate that cyclin E2 is a bona ®de CDK2 partner.
In transiently transfected SAOS-2 cells, co-expression of cyclin E with the Retinoblastoma protein (pRb) induces pRb phosphorylation and prevents pRbinduced G1 arrest (Hinds et al., 1992) . While these results were reproduced with our E HA construct, transfection of the E2 HA plasmid was unable to prevent pRb-induced arrest in SAOS-2 cells (data not shown). Similar results were obtained when assaying the ability of E2
HA or E HA to bypass p16-induced arrest in U2OS cells (Lukas et al., 1997) . However, as seen in 293T, the E HA protein accumulated to much higher levels than E2 HA in SAOS-2 and U2OS cells. Overexpression of cyclin E or E HA and not merely kinase activity, may be critical for biological activity in these assays, and E2
HA may simply fail to accumulate to sucient levels. Thus, further investigations will be required to address the ability of cyclin E2 to induce phosphorylation of pRb, p107 or p130 in vivo, to bypass p16-induced arrest, or to accelerate G1-S progression.
Northern blot analysis of human cell lines (the same cells as in Figure 3c ) revealed a single species of cyclin E2 mRNA migrating at a size of 2.6 kb, slightly larger than cyclin E mRNA, expressed at roughly similar levels in all cells (data not shown). Probing one series of human tissue mRNA blots (Clontech) revealed low but detectable cyclin E2 mRNA levels in various tissues including thymus, prostate, brain, skeletal muscle and kidney, and elevated levels in the lung. A mouse tissue blot yielded a dierent pattern, with high levels in testis and low levels in heart, brain, spleen and liver (data not shown). Database searches revealed several human cyclin E2 ESTs originating from diverse normal tissues, including germinal center B-cells (13 ESTs), retina (4), placenta (2), pregnant uterus (2), aorta (1) and testis (1), fetuses (7) and a variety of tumors (12). More detailed studies of cyclin E2 Figure 3 Characterization of cyclin E2 expression and activity in human cells. (a) Immunoblot analysis of cyclin E2 expression in 293Tcells (with antiserum 3b). Where indicated (+), cells were transfected with a cyclin E2 expression vector (CMV-E2), either alone of with a CMV-p27 vector. Cells where treated for 10 h with 50 mM LLnL (Sigma, A-6185) or the calpain-speci®c inhibitor LLm (Calbiochem, no. 208721) as indicated. Note that cyclin E2 stabilization seen with LLnL is largely lost with LLm, suggesting that cyclin E2 is a substrate of the ubiquitin/ proteasome pathway. The asterisk indicates a non-speci®c crossreacting band running below cyclin E2. (b) Cyclin E2 (antibodies 2b, 4b and 6) or cyclin E were immunoprecipitated from growing 293T cells, followed by H1-kinase assays (H1) or immunoblotting with CDK2 antibodies. As control, each antibody was preblocked with its cognate peptide, as indicated (+). The bands visible on the immunoblot following IP with blocked sera 2b and 4b are non-speci®c contaminants, distinct from CDK2, and are lost upon anity-puri®cation of the antibodies (e.g. here, serum 6). (c) Cyclins E2 (antiserum 6) or E were immunoprecipitated from the indicated cell lines, followed by H1-kinase assays. (d) 293T cells were transfected with expression plasmids (CMV) encoding HA-tagged cyclins E2 (E2 HA ) or E (E HA ). Equal amounts of cell lysates were directly immunoblotted and probed with anti-HA antibodies (upper panel) or immunoprecipitated with anti-HA, followed by immunoblotting with anti CDK2 (middle panel) or H1-kinase assays (lower panel) expression in humans and mice will be required to elucidate its precise expression patterns during embryogenesis, adult life and oncogenesis.
We next examined whether cyclin E2 expression and activity are regulated in a cell cycle-dependent manner. An asynchronous culture of Jurkat T-cells was fractionated by elutriation and mRNA expression analysed by Northern blotting. Cyclin E and E2 mRNA levels¯uctuated with similar patterns, peaking in late G1, before cyclin A mRNA (Figure 4a ), as expected Ko et al., 1992; Pagano et al., 1992) . Similar observations were made upon serum-stimulation of T98G glioblastoma cells ( Figure  4b ). Consistent with mRNA levels, the kinase activities associated with cyclins E, E2 and A were low at quiescence and during early G1 in T98G cells ( Figure  4b ). As shown previously Ko et al., 1992) , cyclin E-associated activity peaked in late G1 and decreased during S phase. Cyclin E2 activity raised in parallel with that of Cyclin E, but reached its maximal level with a 2-h delay (Figure 4b, 16 and 18 h). More strikingly, cyclin E2 activity did not decline until the end of S phase. Thus, during S phase, the kinase activity associated cyclin E2 was elevated, while that of cyclin E had already declined and that of cyclin A was not yet maximal ( Figure 4b ). This particular pattern of cyclin E2 activation in T98G cells was reproducibly observed in three independent experiments.
Cyclin E2-associated kinase was also activated upon cell cycle re-entry in the human breast carcinoma cell line MCF-7 and in normal, ®nite lifespan human mammary epithelial cells (HMEC) strain 184 ( Figure  4c and d) . Similar to T98G, but unlike HMEC184 cells, MCF-7 cells showed delayed and sustained activation of cyclin E2 compared to cyclin E. These observations raise the possibility that sustained cyclin E2 activity in S phase is a property of transformed cells, although larger surveys will be required to address this question.
In quiescent cells (Figure 4c and d, 0 h), we detected cyclin E2-associated CDK2, p27 and p21 proteins, most likely re¯ecting residual levels of cyclin E2 present within CKI-inhibited CDK2 complexes. The rise in cyclin E2 activity correlated with an increase in cyclin E2-associated CDK2, predominantly in its faster-migrating, CAK-phosphorylated form ( Figure  4c , 10 ± 24 h; 4d, 10 ± 16 h). Although the association of cyclin E2 with p21 (as well as p27 in MCF-7) also transiently increased during cell cycle entry, this increase was apparently lower than that of the cyclin E2-CDK2 interaction, suggesting that active cyclin E2/ CDK2 complexes superseeded CKI levels. It is noteworthy that cyclin E-associated p21 has been shown to fall as MCF-7 cells re-enter the cell cycle (Planas-Silva and Weinberg, 1997) ; it will thus be interesting to investigate whether cyclin E2 has a role in titrating CKIs away of cyclin E in vivo. Altogether, our data suggest that cyclin E2/CDK2 complexes are regulated by p21, p27 and CAK in vivo. The mechanisms controlling the dierent patterns of cyclin E2 and E activities remain to be elucidated and may include dierential control of cyclin E2 biosynthesis and/or degradation, dierential regulation of cyclin E2/ CDK2 complexes (e.g. by CKIs, CAK or cdc25A), or the contribution of a dierent CDK partner. T98G glioblastoma cells, (c) MCF-7 and (d) HMEC184 cells were arrested and re-stimulated at time=0 (as described in Materials and methods). Samples were collected at the indicated time points (hours) and used either for mRNA analysis, or for immunoprecipitation of cyclins (E, E2 or A) followed by H1-kinase assays or immunoblot analysis of CDK2, p27 and p21, as indicated. Percentages of S phase cells in each sample (%S) were determined by¯uorocytometric analysis. Early samples contained almost excusively G0/G1cells
In Drosophila, cyclin E is a regulator of both the G1/ S transition (Knoblich et al., 1994) and of passage through S phase (Lilly and Spradling, 1996) . Unlike in vertebrates, cyclin A does not associate with CDK2 in Drosophila (Knoblich et al., 1994) . Since mammalian cyclins E2 and E are equidistant from Drosophila cyclin E (Figure 1) , it seems possible that the two mammalian cyclins have specialized during evolution to perform distinct functions, all attributable to cyclin E in the¯y. In mammalian cells, CDK2 appears to have essential function(s) in G1-S progression, in addition to its role in phosphorylating pRb-family proteins (e.g. Alevizopoulos et al., 1998; Amati et al., 1998 and references therein) . We speculate that cyclin E2 may not be simply redundant with cyclin E, but may possibly regulate distinct rate-limiting step(s). In addition, cyclin E2 may ful®l specialized functions during development. Addressing these questions will require identi®cation of cyclin E and E2 substrates (either common or unique) as well as deletion of the murine cyclin E and E2 genes.
Materials and methods
For two-hybrid screens in yeast, we used a bait containing the DNA-binding domain of the human serum-response factor (SRF) (Amati et al., 1992; Dalton and Treisman, 1992) fused to the human p27
Kip1 protein (Polyak et al., 1994b; Toyoshima and Hunter, 1994) . We screened a cDNA library from the human B-cell line Raji, expressing cDNA products fused to the VP16 transactivation domain (Reith, unpublished) . We used a yeast strain in which two copies of an integrated SRE-CYC1 promoter drive expression of two reporter genes, lacZ (Dalton and Treisman, 1992) and HIS3 (Patel and Jones, unpublished data). This promoter is responsive to an SRF-VP16 hybrid (Dalton and Treisman, 1992) or to co-expression of an SRF-Myc bait and an interacting VP16-Max prey (Amati et al., 1992) . Coexpression of the SRF-p27 bait with the SRF-interacting prey VP16-SAP1 (Dalton and Treisman, 1992) strongly transactivated the reporters, indicating that the bait was expressed and functional in DNA binding. The VP16-cyclin E2 prey isolated in our screen contained residues 117 ± 238 of cyclin E2 (Figure 1a ) and interacted selectively with SRF-p27, but not with SRF alone.
Antisera were raised by injecting rabbits (Elevage Scienti®que des Dombes, France) with KLH-conjugated peptides (Hancock and Evan, 1998) . The following peptides were derived from the human cyclin E2 sequence: KSTEKPPGKH (peptide 395, antiserum 6), SRRSSRLQAKQQPQPSQTES (peptide 2, antiserum 2b) and GQLSPVCNGGIMTPPKSTEKPPGKH (peptide 380, antisera 3b and 4b). The following antibodies were also used; against CDK2: M2 (Santa Cruz sc-163); CDK1: CDC2(17) (sc-54); CDK3: ab1 (NeoMarkers); CDK4: C22 (sc-260); cyclin A: H-432 (sc-751); cyclin E: C19 (sc198) and mAb E172 ; cyclin D1: 72-13G (sc-450); p27: K25020 (Transduction Laboratories); p21: C19 (sc-397).
The human cyclin E2 cDNA was subcloned into the baculovirus transfer vector pVL1393 and co-transfected with BaculoGold TM DNA into Sf9 cells. The recombinant Cyclin E2 baculovirus was ampli®ed for three rounds according to supplier's protocols (Pharmingen). Baculoviruses expressing human cyclins E and A, CDK1, CDK2 and CDK3 were kindly provided by Wade Harper and David Morgan. Human cell lines were grown in DMEM or RPMI (Gibco BRL 31966-021 and 61870-010) with 10% fetal calf serum. 293T cells were transiently transfected with a standard Calcium phosphate-DNA precipitation procedure.
For studies of cell cycle regulation, subcon¯uent T98G glioblastoma cells were serum-starved for 3 days prior to restimulation with 20% FCS and harvesting of samples at various time-points. The ®nite lifespan HMEC184 cells were derived from a human reduction mammoplasty specimen by M Stampfer as described (Stampfer, 1985) . Cells at passage 12 were synchronized in G0 by interruption of EGFdependent signalling for 48 h and released into cycle by readdition of complete medium as described (Sandhu et al., 1997) . MCF-7 cells were rendered quiescent by estradiol depletion and re-entered the cell cycle on re-addition of estradiol (Stampfer, 1985) . Separation of Jurkat T-cells by elutriation was performed with a Beckman JE6B centrifuge, in a JS5.0 rotor with a 4 ml separation chamber turning at 3000 r.p.m. 46108 cells were loaded with at a¯ow rate of 18 ml/min at 48C in PBS with 0.1% FCS. 17 consecutive fractions of 100 ml were collected by increasing medium¯ow-rate from 20 ± 63 ml/min. Samples of elutriated or synchronized cells were analysed by¯ow cytometry for cellular DNA content. Analysis of cyclin/CDK complexes in insect or human cell lysates by immunoprecipitation, immunoblots and kinase assays were performed as previously described (Vlach et al., 1996; Sandhu et al., 1997) . Northern (RNA) blot analysis was as described .
